Total Payments
$214,659
2024 Payments
$7,657
Companies
17
Transactions
1,162
Medicare Patients
17
Medicare Billing
$1,358
Payment Breakdown by Category
Other$182,126 (84.8%)
Food & Beverage$24,024 (11.2%)
Travel$5,126 (2.4%)
Consulting$3,123 (1.5%)
Education$260.98 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $182,126 | 124 | 84.8% |
| Food and Beverage | $24,024 | 946 | 11.2% |
| Travel and Lodging | $5,126 | 78 | 2.4% |
| Consulting Fee | $3,123 | 2 | 1.5% |
| Education | $260.98 | 12 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $93,335 | 372 | $0 (2024) |
| Alkermes, Inc. | $49,600 | 165 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $48,001 | 334 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $16,955 | 201 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $3,104 | 15 | $0 (2024) |
| Allergan Inc. | $1,753 | 18 | $0 (2018) |
| Teva Pharmaceuticals USA, Inc. | $771.35 | 19 | $0 (2024) |
| ITI, Inc. | $451.69 | 21 | $0 (2023) |
| Neurocrine Biosciences, Inc. | $279.89 | 2 | $0 (2024) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $94.36 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,657 | 73 | Otsuka America Pharmaceutical, Inc. ($5,825) |
| 2023 | $16,384 | 101 | Otsuka America Pharmaceutical, Inc. ($11,872) |
| 2022 | $24,781 | 126 | Otsuka America Pharmaceutical, Inc. ($12,527) |
| 2021 | $16,581 | 141 | Otsuka America Pharmaceutical, Inc. ($11,696) |
| 2020 | $17,694 | 110 | Otsuka America Pharmaceutical, Inc. ($13,039) |
| 2019 | $28,431 | 158 | Otsuka America Pharmaceutical, Inc. ($11,535) |
| 2018 | $44,416 | 205 | Sunovion Pharmaceuticals Inc. ($14,830) |
| 2017 | $58,714 | 248 | Sunovion Pharmaceuticals Inc. ($24,557) |
All Payment Transactions
1,162 individual payment records from CMS Open Payments — Page 1 of 47
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/29/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $19.72 | General |
| Category: Psychiatry/Psychology | ||||||
| 10/25/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $26.87 | General |
| Category: PSYCHIATRY | ||||||
| 10/22/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $25.69 | General |
| Category: Neuroscience | ||||||
| 10/19/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $27.58 | General |
| Category: Neurology | ||||||
| 10/11/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $30.79 | General |
| Category: Neurology | ||||||
| 10/10/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $25.05 | General |
| Category: Neuroscience | ||||||
| 10/03/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $139.89 | General |
| Category: Neuropsychiatry | ||||||
| 10/03/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $30.67 | General |
| 09/20/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $33.42 | General |
| Category: Neurology | ||||||
| 09/19/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $25.09 | General |
| Category: Neuroscience | ||||||
| 08/22/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $38.99 | General |
| Category: Neuroscience | ||||||
| 08/21/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug), ABILIFY ASIMTUFII | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $877.50 | General |
| Category: PSYCHIATRY | ||||||
| 08/20/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $30.22 | General |
| Category: Neuroscience | ||||||
| 08/13/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $15.06 | General |
| 08/09/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $24.99 | General |
| Category: CNS | ||||||
| 08/08/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $27.19 | General |
| 07/30/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $26.58 | General |
| Category: CNS | ||||||
| 07/26/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $30.36 | General |
| Category: Neurology | ||||||
| 07/18/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $28.80 | General |
| Category: Neuroscience | ||||||
| 07/16/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $22.48 | General |
| Category: Neurology | ||||||
| 07/12/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: CNS | ||||||
| 07/11/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $37.35 | General |
| Category: Neuroscience | ||||||
| 06/25/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $21.23 | General |
| Category: Neuroscience | ||||||
| 06/20/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug) | Food and Beverage | In-kind items and services | $27.13 | General |
| Category: PSYCHIATRY | ||||||
| 06/14/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $23.11 | General |
| Category: Neurology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 1 | 17 | 34 | $6,708 | $1,358 |
Total Patients
17
Total Services
34
Medicare Billing
$1,358
Procedure Codes
1
All Medicare Procedures & Services
1 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 17 | 34 | $6,708 | $1,358 | 20.2% |
About Dr. Ramesh Patel, M.D
Dr. Ramesh Patel, M.D is a Psychiatry healthcare provider based in Riverside, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/31/2007. The National Provider Identifier (NPI) number assigned to this provider is 1912044520.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ramesh Patel, M.D has received a total of $214,659 in payments from pharmaceutical and medical device companies, with $7,657 received in 2024. These payments were reported across 1,162 transactions from 17 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($182,126).
As a Medicare-enrolled provider, Patel has provided services to 17 Medicare beneficiaries, totaling 34 services with total Medicare billing of $1,358. Data is available for 1 year (2020–2020), covering 1 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Riverside, CA
- Active Since 01/31/2007
- Last Updated 07/08/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1912044520
Products in Payments
- ABILIFY MAINTENA (Drug) $65,261
- LATUDA (Drug) $47,844
- ARISTADA (Drug) $26,929
- REXULTI (Drug) $25,666
- Aristada 441 mg (Drug) $22,671
- INVEGA SUSTENNA (Drug) $8,630
- INVEGA TRINZA (Drug) $8,266
- ABILIFY ASIMTUFII (Drug) $2,705
- VRAYLAR (Drug) $1,729
- CAPLYTA (Drug) $546.05
- UZEDY (Drug) $518.68
- INGREZZA (Drug) $279.89
- APTIOM (Drug) $157.77
- Austedo XR (Drug) $124.99
- Repatha (Biological) $88.03
- SPRAVATO (Drug) $67.47
- BELSOMRA (Drug) $39.68
- COBENFY (Drug) $19.72
- BRINTELLIX (Drug) $19.05
- AUSTEDO (Drug) $16.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Riverside
Dr. David Seigler, M.d, M.D
Psychiatry — Payments: $34,624
Psychiatry $34,624
Richard Kotomori, M.d, M.D
Psychiatry — Payments: $17,432
Psychiatry $17,432
Dr. Monissa Solberg, Md, MD
Psychiatry — Payments: $12,546
Psychiatry $12,546
Dr. Robert Summerour, Md, MD
Psychiatry — Payments: $8,186
Psychiatry $8,186
Lisa Frappier, Do, DO
Psychiatry — Payments: $4,955
Psychiatry $4,955
Dr. Samuel Dey, M.d, M.D
Psychiatry — Payments: $3,776
Psychiatry $3,776